Seeking Alpha

CombiMatrix rises on deal with pathology service provider

  • Pathology service provider ProPath selects CombiMatrix (CBMX) to "provide its chromosomal microarray analysis testing for miscarriage analysis."
  • "For an important group of patients, CMA testing can play a significant role in a comprehensive miscarriage analysis," a ProPath director notes.
  • CBMX says the agreement is "yet another validation of the quality of [its] diagnostic services." (PR)
  • CBMX +14% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|